CNS Pharmaceuticals Inc. (CNSP)
NASDAQ: CNSPHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CNSP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.82M
- EPS (TTM)
- -$17.90
- Dividend yield
- None
- 52-week range
- 1.90 – 10.54
- Day range
- 5.35 – 5.36
- Volume / Avg
- 1.74K / 6.40K
- Beta
- —
- Shares outstanding
- 1.46M
52-week range
CNSP stock today
Shares of CNS Pharmaceuticals (CNSP) finished lower on Oct 8 at $5.35, a drop of 1.47% or $0.08 per share, versus the S&P 500's 0.47% decline. Trading was light, with 1.74K shares changing hands, about 27% of the average daily volume. At this level, CNSP sits in the middle of its 52-week range of $1.90 to $10.54: 49.2% below the high and 181.6% above the low.
CNS Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$17.90), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CNS Pharmaceuticals
Company profileCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Rami Levin M.B.A.
- Headquarters
- Houston, TX
- Employees
- 8
- IPO year
- 2019
- Website
- cnspharma.com
Analyst forecast
ForecastConsensus
none
Avg. price target
$10.00+86.92%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
CNS Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AZTRAzitra Inc | 0.132 | 0.00% | $8.00M | vs CNSP |
| FBLGFibroBiologics Inc. | 1.11 | -2.63% | $7.72M | vs CNSP |
| LGVNLongeveron Inc. Class A | 2.37 | -2.87% | $7.56M | vs CNSP |
| SNGXSoligenix Inc. | 0.3466 | -1.95% | $7.54M | vs CNSP |
| CLGNCollPlant Biotechnologies Ltd | 3.97 | +14.74% | $7.51M | vs CNSP |
| CURXCuranex Pharmaceuticals Inc | 4.76 | -0.94% | $7.46M | vs CNSP |
| SKYESkye Bioscience Inc. | 1.68 | +1.82% | $7.44M | vs CNSP |
| TRAWTraws Pharma Inc. | 0.4803 | +0.27% | $7.38M | vs CNSP |
Indexes, lists and sector
Appears in lists
CNS Pharmaceuticals stock FAQ
What is CNS Pharmaceuticals's stock price today?
CNSP last traded at $5.35 as of Oct 8, 4:00 PM EDT, down 1.47% on the day. Prices are delayed at least 15 minutes.
Who is CNS Pharmaceuticals's CEO?
Mr. Rami Levin M.B.A. is the chief executive officer of CNS Pharmaceuticals Inc., which has about 8 employees.
What is the CNSP 52-week high?
The 52-week high for CNSP is $10.54 and the 52-week low is $1.90. The stock is currently 49.2% below its high.